Seres Therapeutics, Inc. $MCRB

By Microcap Ledger desk · CIK 0001609809

Facts as of Oct 11, 2026, 08:15 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Select Market
Sector: Pharmaceutical Preparations
Headquarters: Cambridge, MA
Fiscal year end: December 31
Shares outstanding: 9,941,261 [10-Q 2026-08-05]
as of 2026-08-03

Sources: [10-K 2026-03-12]

What the company doesAI summary of filing

Seres Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products (LBPs), which are consortia of bacteria designed for oral delivery to treat infectious diseases and inflammatory and immune conditions. The company previously developed and sold VOWST, the first FDA-approved orally administered microbiome therapeutic, to Nestlé Health Science in September 2024. Seres is currently advancing SER-155 for allogeneic hematopoietic stem cell transplantation patients and immune checkpoint-related enterocolitis, SER-603 for inflammatory bowel disease, and SER-147 for chronic liver disease, supported by its proprietary MbTx Platform for drug discovery. The company is pre-revenue from product sales, though it received milestone payments from the VOWST transaction, and operates in clinical development stage with ongoing funding needs. [10-K 2026-03-12]

Segments: SER-155, SER-603, SER-147, VOWST (sold)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	$1.09M	−$15.33M	−$38.75M	$15.59M	[10-Q 2026-08-05]
FY ended Dec 2025	$789.0K	$5.70M	$1.12M	$45.77M	[10-K 2026-03-12]
FY ended Dec 2024	$0.00	$136.0K	−$148.61M	$30.79M	[10-K 2026-03-12]

Quarterly cash burn: −$19.38M
Cash runway Estimate: ~2.4 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-08-09	151,730,995	[10-Q 2024-08-13]
2024-11-08	170,738,069	[10-Q 2024-11-13]
2025-03-07	174,358,753	[10-K 2025-03-13]
2025-05-02	8,732,422	[10-Q 2025-05-07]
2025-08-01	8,754,570	[10-Q 2025-08-06]
2025-10-31	9,046,519	[10-Q 2025-11-05]
2026-03-06	9,586,298	[10-K 2026-03-12]
2026-08-03	9,941,261	[10-Q 2026-08-05]

Shelf registration: S-3 filed 2026-08-13; declared effective 2026-08-21 [S-3 2026-08-13]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-11-13. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2024-11-13	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2024-11-13]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-08-17	Brady Kelly	sell	64	$4.55	[4 2026-08-18]
2026-08-17	Shaff Eric D.	sell	263	$4.55	[4 2026-08-18]
2026-08-17	Henn Matthew R	sell	81	$4.55	[4 2026-08-18]
2026-08-17	Desrosier Thomas	sell	82	$4.55	[4 2026-08-18]
2026-08-15	Brady Kelly	exercise	181	—	[4 2026-08-18]
2026-08-15	Shaff Eric D.	exercise	722	—	[4 2026-08-18]
2026-08-15	Henn Matthew R	exercise	238	—	[4 2026-08-18]
2026-08-15	Desrosier Thomas	exercise	245	—	[4 2026-08-18]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-13	S-3	Registration statement
2026-08-05	10-Q	Quarterly report
2026-08-05	8-K	Results of operations
2026-08-04	8-K	Material agreement entered; Material agreement terminated
2026-08-04	424B5	Prospectus or prospectus supplement
2026-07-08	8-K	Director or officer change; Shareholder vote results
2026-07-08	8-K	Regulation FD disclosure; Other events
2026-06-05	8-K	Material agreement entered; Regulation FD disclosure
2026-06-01	8-K	Director or officer change
2026-05-05	10-Q	Quarterly report
2026-05-05	8-K	Results of operations
2026-04-27	DEF 14A	Proxy statement

Facts as of Oct 11, 2026, 08:15 AM UTC. Small caps move fast; check the latest filings.